Processa Pharmaceuticals, Inc.

PCSA • Biotechnology

$2.06

▲ +0.01 (+0.49%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$5.67M

Growth

-100.0%

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0Healthy liquidity · 2.54Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:21 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$2.06

Change0.49%

Shares Out2.75M

Market Cap$5.67M

Enterprise Value$5.47M

52W Range1.67 - 14.25

Beta0.96

P/E-0.42

P/B-17.86

P/FCF-0.44

EV/EBITDA-0.54

EV/FCF-0.43

Price$2.06

Change0.49%

Shares Out2.75M

Market Cap$5.67M

Enterprise Value$5.47M

52W Range1.67 - 14.25

Beta0.96

P/E-0.42

P/B-17.86

P/FCF-0.44

EV/EBITDA-0.54

EV/FCF-0.43

Earnings Yield-237.15%

FCF Yield-226.27%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio2.54

Quick Ratio2.54

Revenue 5Y-100.00%

Target$225.00

Target Upside10822.33%

Target Median$225.00

Target Range225.00 - 225.00

Volume49.90K

Avg Volume193.12K

EPS Surprise-0.29

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

70/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

95/100

Why this score▼

Manageable debt level · 0Healthy liquidity · 2.54Weak profitability

Analyst view

Analyst sentiment and price target

PCSA

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

90/100

Bullish

Hold

Bearish

Price Target

2026-08-16

Low

$225.00

Mean

$225.00

Median

$225.00

High

$225.00

Company Overview

IPO: 3/7/2014

Industry: Biotechnology

P/B i: -17.86

Debt / Equity i: 0.00

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: 0.00

Current Ratio: 2.54

Quick Ratio: 2.54

Status: Good

Insider Transactions

Recent executive and insider activity

Ng George K

Transaction: 08/08/2026

BUY

Change

+1,600

Price

Not reported

Filing

08/11/2026

Type

BUY

Ng George K

Transaction: 08/08/2026

SELL

Change

-1,600

Price

Not reported

Filing

08/11/2026

Type

SELL

GUJRATHI SHEILA

Transaction: 07/28/2026

OTHER

Change

Price

Not reported

Filing

07/30/2026

Type

OTHER

Insider	Type	Change	Price	Transaction	Filing
Ng George K	BUY	+1,600	Not reported	08/08/2026	08/11/2026
Ng George K	SELL	-1,600	Not reported	08/08/2026	08/11/2026
GUJRATHI SHEILA	OTHER	0	Not reported	07/28/2026	07/30/2026
GUJRATHI SHEILA	BUY	—	Not reported	07/28/2026	07/30/2026
Baluch Khoso	BUY	+33,500	Not reported	07/26/2026	07/28/2026
Guy Wendy	BUY	+9,450	Not reported	07/26/2026	07/28/2026
Lin Patrick	BUY	+8,450	Not reported	07/26/2026	07/28/2026
Neal James R	BUY	+62,221	Not reported	07/26/2026	07/28/2026
Ng George K	BUY	+9,384	Not reported	07/26/2026	07/28/2026
Pannu Geraldine	BUY	+33,500	Not reported	07/26/2026	07/28/2026
SKIBSTED RUSSELL	BUY	+11,883	Not reported	07/26/2026	07/28/2026
Yorke Justin W	BUY	+33,500	Not reported	07/26/2026	07/28/2026
Ng George K	BUY	+3,057	$1.93	07/01/2026	07/01/2026
Young David	BUY	+2,531	$1.93	06/30/2026	07/01/2026
SKIBSTED RUSSELL	BUY	+3,277	$1.93	06/30/2026	07/01/2026
Lin Patrick	BUY	+2,106	$1.93	06/30/2026	07/01/2026
Guy Wendy	BUY	+2,436	$1.93	06/30/2026	07/01/2026
Baluch Khoso	BUY	+203	Not reported	06/26/2026	06/30/2026
Baluch Khoso	SELL	-203	Not reported	06/26/2026	06/30/2026
Neal James R	BUY	+203	Not reported	06/26/2026	06/30/2026

About the Company

Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.

Source - link

Peers

ALLR ATHA BCTX CRIS CTXR ENTO HOTH LPTX MBRX PALI

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

VERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced its participation in two upcoming investor conferences.

GlobeNewsWire

Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript

Seeking Alpha

Processa buys Vidya Therapeutics, raises $200 million for drug trials

Processa Pharmaceuticals said on Wednesday it acquired privately held Vidya Therapeutics in an all-stock deal, gaining access to its lead candidate ‌being developed to target diseases involving the immune system.

Reuters

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC.

Acquisition brings into Processa's pipeline Vidya's lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton's tyrosine kinase inhibitor (BTKi) designed to overcome the efficacy and safety limitations of early-generation BTKi programs Concurrent oversubscribed private placement financing of approximately $200 million committed by a syndicate of leading healthcare institutional investors and mutual funds Private placement proceeds are expected to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS) Processa to host investor webcast on July 29, 2026, at 8:30 a.m. ET VERO BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Processa) (Nasdaq: PCSA) today announced it has acquired Vidya Therapeutics, Inc. (Vidya), a clinical-stage biotechnology company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases with an initial focus on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	-1	-1.29	-0.29
2026-03-19	-1.5	-18.5	-17
2025-11-06	-2	-1.75	0.25
2025-08-07	-0.23	-0.25	-0.02
2025-05-08	-0.77	-0.3	0.47
2025-03-20	-0.92	-0.74	0.18
2024-10-30	-1	-1.03	-0.03
2024-08-13	-0.98	-1.01	-0.03
2024-05-10	-1.18	-1.11	0.07
2024-03-29	-1.6	-0.24	1.36
2023-11-13	-0.1	-1.6	-1.5
2023-08-10	-3	-2	1